Capricor Therapeutics Inc (NASDAQ:CAPR) Position Boosted by Legal & General Group Plc

Legal & General Group Plc boosted its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 1,029.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 30,783 shares of the biotechnology company's stock after buying an additional 28,058 shares during the quarter. Legal & General Group Plc owned approximately 0.07% of Capricor Therapeutics worth $425,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its position in Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock worth $1,536,000 after acquiring an additional 37,868 shares in the last quarter. Magnus Financial Group LLC acquired a new stake in Capricor Therapeutics during the 4th quarter valued at $276,000. JPMorgan Chase & Co. lifted its holdings in Capricor Therapeutics by 419.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock worth $855,000 after buying an additional 45,381 shares in the last quarter. Swiss National Bank purchased a new position in Capricor Therapeutics in the 4th quarter valued at about $930,000. Finally, Alliancebernstein L.P. purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $183,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Stock Down 15.0 %

Shares of NASDAQ:CAPR traded down $1.78 on Monday, reaching $10.09. 559,173 shares of the company's stock were exchanged, compared to its average volume of 1,513,781. Capricor Therapeutics Inc has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The business's 50-day moving average is $11.84 and its two-hundred day moving average is $14.58. The firm has a market capitalization of $460.65 million, a price-to-earnings ratio of -9.58 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. The firm had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. Analysts predict that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on CAPR shares. HC Wainwright restated a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reiterated an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics has an average rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.